Sage Therapeutics Shares Plummet on Subpar Depression-Treatment Study Results - WSJ
/cloudfront-us-east-1.images.arcpublishing.com/bostonglobe/5L4UQNLAORLRMH6HCPVSUTPQUE.JPEG "Sage Therapeutics to lay off about 40 percent of its workforce - The Boston Globe")
Sage Therapeutics to lay off about 40 percent of its workforce - The Boston Globe
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics slumps, Biogen bounces
Oppenheimer cuts Sage Therapeutics to perform, cites FDA setback (NASDAQ: SAGE) | Seeking Alpha
Sage Therapeutics Restructures To Support ZURZUVAE Launch | Contract Pharma
Rx Product News: April 2023
Sage Therapeutics stock falls after stock offering, Q3 miss | Seeking Alpha
SAGE Therapeutics News, SAGE Therapeutics Quote, SAGE Quote - StreetInsider.com
Did SAGE Therapeutics Just Break the CNS Curse? | BioSpace
Sage rethinks SAGE-217 program after phase 3 failure | Fierce Biotech
Sage Therapeutics plunges after FDA decision on depression drug
Why Is Sage Therapeutics (SAGE) Stock Down 48% Today? | InvestorPlace
Sage Therapeutics Inc (SAGE) Announces Q3 2023 Financial Results and Highlights Pipeline Progress
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected
Sage Therapeutics (@SageBiotech) / X
Sage Therapeutics fires 40% of staff after FDA rejected MDD bid - Pharmaceutical Technology
Biogen Gives Sage Therapeutics $1.5 Billion In Deal To Develop Depression And Tremor Treatments | The Healthcare Technology Report.
Biotech layoffs 2023: Sage Therapeutics cuts nearly half its staff in wake of partial FDA rejection - Boston Business Journal
Sage Therapeutics CEO: Mental health is integral to returning to work
Sage Therapeutics CEO on drugs in development, addressing mental health
Sage Therapeutics
Sage Therapeutics (@SageBiotech) / X
FDA approval for zuranolone offers hope in postpartum depression
